Abstract
Intaking antithrombotic funds (ATA) and non-steroidal anti-inflammatory drugs (NSAIDs) is one of the most frequent causes of pathology in gastrointestinal (GI) tract.The purpose of the study: comparison of pathological changes of the mucous membrane in the upper GI tract, that occur against the background of ATA and NSAIDs admission.Material and methods. Endoscopic data of two groups of patients taking ATA and NSAIDS have been compared. The first group of 448 patients from the 10th Gastrointestinal Department in N.N. Burdenko Main Military Clinical Hospital was on record from 2013 to 2017. The patients had erosive ulcerous changes of gastrointestinal mucosa, occurred against the background of the ATA admission. The second group comprised 6431 patients with rheumatic diseases. They were hospitalized in the clinic of V.A. Nasonova Research Institute of Rheumatology in the period from 2007 to 2016 and took NSAIDs regularly.Results. Duodenal and gastric ulcer changes in gastric mucosa and duodenal ulcers were identified in 168 (37.5 %) patients taking ATA and in 1691 (26.3 %) patient treated with NSAIDS. Structure of pathology varied. So, against the background of ATA and NSAIDS admission, the number of acute gastric ulceration amounted to 6.5 % and 15.5 % (p < 0.001); acute ulcers duodenal was 2.9 % and 4.9 %; combined ulcerative lesions of gastric and duodenal was 2.9 % and 2.0 %; multiple erosions of gastroduodenal mucosa were 52.4 % and 15.7 % (p < 0.001); single erosion was 35. 1% and 61.6 %. The factor of ulcer history and age ≥ 65 years old increased significantly the risk of duodenal and gastric ulcer changes in patients taking ATA and NSAIDs: OR 5.182 (95% CI 2.701–9.942) and 3.24 (95% CI 2.19–5.34), 4.537 (95% CI 2.036–10.11) and 2.016 (95% CI 1.230–2.917) respectively. Intaking of proton pump inhibitor (PPI) reduced significantly the risk of complications for both ATA and NSAIDs: OR 0.329 (95% CI 0.199–0.546) and 0.317 (95% CI 0.210–0.428) respectively.Conclusion. The structure of pathology of mucous in the upper gastrointestinal tract that arose against the backdrop of ATA and NSAIDs admission is different. The first is characterized by a multiple erosion, while the second one has single acute distal gastric ulcers. The ulcerative history and advanced age of patients increase significantly the risk of complications concerning the gastroduodenal mucosa when using ATA and NSAIDs. PPI is the effective means of preventing this pathology.
Highlights
Резюме Цель исследования: cравнение патологических изменений слизистой оболочки (СО) верхнего отдела желудочно-кишечного тракта (ЖКТ), возникающих на фоне приёма антитромботических средств (АТС) и нестероидных противовоспалительных препаратов (НПВП)
Duodenal and gastric ulcer changes in gastric mucosa and duodenal ulcers were identified in 168 (37.5 %) patients taking Abstract Intaking antithrombotic funds (ATA) and in 1691 (26.3 %) patient treated with NSAIDS
Against the background of ATA and NSAIDS admission, the number of acute gastric ulceration amounted to 6.5 % and 15.5 % (p < 0.001); acute ulcers duodenal was 2.9 % and 4.9 %; combined ulcerative lesions of gastric and duodenal was 2.9 % and 2.0 %; multiple erosions of gastroduodenal mucosa were 52.4 % and 15.7 % (p < 0.001); single erosion was 35. 1% and 61.6 %
Summary
Сравнение эндоскопической картины при осложнениях со стороны верхних отделов желудочно-кишечного тракта, вызванных приёмом антитромботических средств и нестероидных противовоспалительных препаратов. Резюме Цель исследования: cравнение патологических изменений слизистой оболочки (СО) верхнего отдела ЖКТ, возникающих на фоне приёма антитромботических средств (АТС) и нестероидных противовоспалительных препаратов (НПВП). Первая группа представлена 448 больными, наблюдавшимися в гастроэнтерологическом отделении, с эрозивно-язвенными изменениями слизистой ЖКТ, возникшими на фоне приёма АТС. Наличие язвенного анамнеза и возраста ≥ 65 лет значительно увеличивали риск развития эрозивно-язвенных изменений у больных, принимавших АТС и НПВП: ОШ 5,182 (95% ДИ 2,701–9,942) и 3,24 (95% ДИ 2,19–5,34), 4,537 (95% ДИ 2,036–10,11) и 2,016 (95% ДИ 1,230–2,917) соответственно. Структура патологии СО верхних отделов ЖКТ, возникшей на фоне приёма АТС и НПВП, различается.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Acta Biomedica Scientifica (East Siberian Biomedical Journal)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
